Autopsy report · NCT01663662

The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

“Lack of eligible patients”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

University of Michigan

Sponsor type

University, hospital or other

Conditions

Heart Failure

Interventions

Tolvaptan; placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (99% match in meaning)
• Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques
  “Lack of eligible patients willing and able to participate” (93% match in meaning)
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
  “Not enough eligible patients available” (92% match in meaning)
• TRAUMA HELP: Healing and Analgesia With Propranolol
  “Lack of eligible patient recruits/feasibility considerations.” (85% match in meaning)
• African American Families Fighting Parental Cancer Together
  “Insufficient patients meet eligibility requirements.” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.